These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21628141)

  • 1. Insulin pens vs. vials and syringes: differences in clinical and economic outcomes.
    Bastian MD; Wolters NE; Bright DR
    Consult Pharm; 2011 Jun; 26(6):426-9. PubMed ID: 21628141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin pens vs. vials and syringes: the pharmacist's role in individualizing therapy.
    Honebrink AN; Peters CR; Bright DR
    Consult Pharm; 2011 Jul; 26(7):491-3. PubMed ID: 21729850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for diabetes: treatment with insulin pen devices.
    Cuddihy RM; Borgman SK
    Am J Ther; 2013; 20(6):694-702. PubMed ID: 21768872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empowering people with diabetes: improving perceptions and outcomes with technical advances in insulin pens.
    Oyer D; Niemeyer M; Moses A
    Postgrad Med; 2012 Sep; 124(5):110-20. PubMed ID: 23095431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization.
    Davis EM; Christensen CM; Nystrom KK; Foral PA; Destache C
    Am J Health Syst Pharm; 2008 Jul; 65(14):1347-57. PubMed ID: 18593681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence.
    Asche CV; Shane-McWhorter L; Raparla S
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S101-8. PubMed ID: 20515297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing barriers to insulin therapy: the role of insulin pens.
    Magwire ML
    Am J Ther; 2011 Sep; 18(5):392-402. PubMed ID: 20838202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
    Eby EL; Boye KS; Lage MJ
    J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nurse satisfaction using insulin pens in hospitalized patients.
    Davis EM; Bebee A; Crawford L; Destache C
    Diabetes Educ; 2009; 35(5):799-809. PubMed ID: 19633151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe.
    Baser O; Bouchard J; DeLuzio T; Henk H; Aagren M
    Adv Ther; 2010 Feb; 27(2):94-104. PubMed ID: 20352392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of diabetes insulin delivery devices.
    Selam JL
    J Diabetes Sci Technol; 2010 May; 4(3):505-13. PubMed ID: 20513314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic outcomes with the conversion of insulin delivery methods in hospitals.
    Kelton KA; Perk S; Loveland S; Perez-Nieves M; Fu H; Peng X
    J Med Econ; 2017 May; 20(5):533-540. PubMed ID: 28133990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact analysis of insulin therapies and associated delivery systems.
    Lee LJ; Smolen LJ; Klein TM; Foster SA; Whiteman D; Jorgenson JA; Hultgren S
    Am J Health Syst Pharm; 2012 Jun; 69(11):958-65. PubMed ID: 22610028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical and health economic review of a prefilled insulin pen.
    Niskanen L
    Curr Med Res Opin; 2010 Oct; 26(10):2431-9. PubMed ID: 20815660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials.
    Asche CV; Luo W; Aagren M
    Curr Med Res Opin; 2013 Oct; 29(10):1287-96. PubMed ID: 23865725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing accuracy of insulin pens versus conventional syringes and vials.
    Luijf YM; DeVries JH
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S73-7. PubMed ID: 20515311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of vials and prefilled pens of a rapid-acting insulin analog on pharmacy budgets in a long-term care setting.
    Eby EL; Smolen LJ; Pitts AC; Krueger LA; Andrews JS
    Consult Pharm; 2014 Dec; 29(12):813-22. PubMed ID: 25521657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin pens: the modern delivery devices.
    Baruah MP
    J Assoc Physicians India; 2011 Apr; 59 Suppl():38-40. PubMed ID: 21823254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing insulin vials to pens--comparison of charges, not healthcare benefits.
    Thethi TK
    J Med Econ; 2013 Oct; 16(10):1228-30. PubMed ID: 23926888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.